Lack of the NS5B S282T mutation in HCV isolates from liver tissue of treatment-naive patients with HCV genotype-1b infection

Antiviral Therapy

Volumn 20, Issue 2, 2015, Pages 245-247

  Maimone, Sergio ^a   Tripodi, Gianluca ^a   Musolino, Cristina ^a   Cacciola, Irene ^a   Pollicino, Teresa ^a,b   Raimondo, Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 5B; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 1B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER; LIVER BIOPSY; MALE; MOLECULAR CLONING; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS MUTATION; BIOPSY; BLOOD; CHEMISTRY; DNA SEQUENCE; ENZYMOLOGY; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; MUTATION; PATHOLOGY; VIROLOGY;

ADULT; BIOPSY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; MUTATION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84937417148     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2844     Document Type: Article

References (15)

1. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2014; 60:392-420.
2. Wendt A, Adhoute X, Castellani P, et al. Chronic hepatitis C: future treatment. Clin Pharmacol 2014; 6:1-17.
3. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132:1979-1998.
4. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2:30ra32.
5. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013; 59:375-382.
6. Aloia AL, Locarnini S, Beard MR. Antiviral resistance and direct-acting antiviral agents for HCV. Antivir Ther 2012; 17:1147-1162.
7. Keating GM, Vaidya A. Sofosbuvir: first global approval. Drugs 2014; 74:273-282.
8. Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39:478-487.
9. Maimone S, Musolino C, Squadrito G, Raffa G, Pollicino T, Raimondo G. NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C. Antivir Ther 2013; 18:131-134.
10. Franco S, Casadella M, Noguera-Julian M, et al. No detection of the NS5B S282T mutation in treatment-naive genotype 1 HCV/HIV-1 coinfected patients using deep sequencing. J Clin Virol 2013; 58:726-729.
11. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81:1631-1648.
12. Verbinnen T, Van MH, Vandenbroucke I, et al. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol 2010; 84:11124-11133.
13. Cubero M, Esteban JI, Otero T, et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008; 370:237-245.
14. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res 2014; 105:64-71.
15. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310:804-811.